An observational study in Keratoconus, Corneal Opacity and Corneal Dystrophy, sponsored by Oregon Health and Science University. Recruiting at 1 site in United States. Open to participants aged 14 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-09.
Sponsored by Oregon Health and Science University · Observational
This main goal of this study is to improve the detection, classification, monitoring, and treatment of irregular corneas due to keratoconus, warpage, dry eye, scar, stromal dystrophies, and other corneal conditions.
The primary goal will be achieved by using optical coherence tomography (OCT) to:
A total of 445 participants ages 14 or older will be recruited for the 3 clinical studies. All 3 studies will be performed at the Casey Eye Institute at Oregon Health \& Science University.
Group A:
GROUP A:
Keratoconus:
Contact lens-related corneal warpage:
Dry eye:
Epithelial basement membrane dystrophy (EBMD):
Stromal addition or subtraction:
Stromal distortion:
Normal controls:
GROUP B:
Participants will be selected from the keratoconus population in Group A based on topography findings.
GROUP C:
Participants will be selected from the stromal addition/subtraction and stromal distortion populations of Group A if they have vision primarily limited by scars, dystrophy, or high astigmatism that could benefit from PTK.
Exclusion Criteria (all groups):
This group will consist of participants \>14 years old with various types of corneal irregularities. Their data will be compared against participants with healthy corneas. Data for this group will be gathered only once.
Device: Optical Coherence Tomography
Participants from Group A who are diagnosed with keratoconus will be selected for this longitudinal study to monitor keratoconus progression. They will be followed up to 4 years.
Device: Optical Coherence Tomography
Participants from Group A will be selected for this group if they have vision primarily limited by scars, dystrophy, or high astigmatism that could be treated by PTK. They will be followed up to 1 year.
Device: Optical Coherence Tomography
This device will be used to tightly classify corneal irregularities and determine eligibility of candidates from Group A into Groups B \& C.
Develop OCT-based system to classify and evaluate corneal-shape irregularities
Clinical classification of keratoconus, epithelial deformation, stromal addition/subtraction, stromal distortion, and healthy controls by OCT. Primary measurements will be corneal and epithelial thicknesses assessed in micron units.
Time frame: 1 day
Develop OCT-based system to classify and evaluate corneal-shape irregularities
Secondary measurement will be OCT corneal shape assessed in Diopter units.
Time frame: 1 day
Develop OCT metrics for more sensitive detection of keratoconus progression
Primary measurements will be OCT corneal and epithelial thicknesses assessed in micron units.
Time frame: 4 year
Develop OCT metrics for more sensitive detection of keratoconus progression
Secondary measurement will be OCT corneal shape assessed in Diopter units.
Time frame: 4 year
Develop OCT- and topography-guided phototherapeutic keratectomy (PTK) for irregular corneas
The primary goal is to improve the post-procedural outcome of uncorrected and best corrected visual acuity. This will be measured in feet by conventional Snellen fraction of 20/xx.
Time frame: 1 year
Develop OCT- and topography-guided phototherapeutic keratectomy (PTK) for irregular corneas
The secondary goal is to improve the post-procedural outcome of refractive error. This will be measured in Diopter units.
Time frame: 1 year
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Oregon Health and Science University